Kiniksa Pharmaceuticals International, plc reported $841M of revenue over the trailing twelve months, +59% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $841M (to Q2 2026). Net income: $81M, trailing twelve months to Q2 2026. Free cash flow: $183M, trailing twelve months to Q2 2026. Operating margin: 12%, trailing twelve months to Q2 2026.

KNSAKiniksa Pharmaceuticals International, plc

Healthcare

$76.71+97% 1Y

$76.71

$37.0152 weeks$83.18

KNSA as reported

Kiniksa Pharmaceuticals International, plc reported $841M of revenue over the trailing twelve months, +59% on the year before. 10 reported series are charted on this page, each one as filed.

$841M

Revenue, trailing twelve months · to Q2 2026 · +59% against the twelve months before

Net income: $81M
Net income · +1584% year on year · trailing twelve months to Q2 2026
Free cash flow: $183M
Free cash flow · +175% year on year · trailing twelve months to Q2 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for KNSA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$841M	+59%	Q2 2026
Net income	$81M	+1584%	Q2 2026
EPS	$0.98	+2350%	Q2 2026
Gross margin	90%	n/a	Q2 2026
Operating margin	12%	n/a	Q2 2026
Net margin	9.6%	n/a	Q2 2026
ROE	10%	n/a	Q2 2026
ROA	7.7%	n/a	Q2 2026
Free cash flow	$183M	+175%	Q2 2026
P/E	78.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.